Bank of New York Mellon’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21.8M | Buy |
245,193
+53,798
| +28% | +$3.93M | ﹤0.01% | 1583 |
|
|
2026
Q1 | $9.65M | Sell |
191,395
-1,435
| -0.7% | -$54.1K | ﹤0.01% | 1954 |
|
|
2025
Q4 | $6.32M | Buy |
192,830
+56,870
| +42% | +$1.49M | ﹤0.01% | 2186 |
|
|
2025
Q3 | $2.28M | Buy |
135,960
+3,810
| +3% | +$62.1K | ﹤0.01% | 2729 |
|
|
2025
Q2 | $1.98M | Buy |
132,150
+17,910
| +16% | +$265K | ﹤0.01% | 2754 |
|
|
2025
Q1 | $1.84M | Buy |
114,240
+10,552
| +10% | +$220K | ﹤0.01% | 2733 |
|
|
2024
Q4 | $2.41M | Sell |
103,688
-1,118
| -1% | -$32.8K | ﹤0.01% | 2677 |
|
|
2024
Q3 | $3.08M | Sell |
104,806
-12,880
| -11% | -$359K | ﹤0.01% | 2551 |
|
|
2024
Q2 | $2.77M | Buy |
117,686
+111,636
| +1,845% | +$3.77M | ﹤0.01% | 2613 |
|
|
2024
Q1 | $229K | Buy |
+6,050
| New | +$175K | ﹤0.01% | 3893 |
|
|
2023
Q3 | – | Sell |
-929
| Closed | -$10.5K | – | 4406 |
|
|
2023
Q2 | $10.5K | Hold |
929
| – | – | ﹤0.01% | 4336 |
|
|
2023
Q1 | $6.74K | Hold |
929
| – | – | ﹤0.01% | 4373 |
|
|
2022
Q4 | $10.5K | Hold |
929
| – | – | ﹤0.01% | 4419 |
|
|
2022
Q3 | $12K | Sell |
929
-76
| -8% | -$939 | ﹤0.01% | 4496 |
|
|
2022
Q2 | $13K | Sell |
1,005
-5,301
| -84% | -$186K | ﹤0.01% | 4534 |
|
|
2022
Q1 | $362K | Sell |
6,306
-65
| -1% | -$5.46K | ﹤0.01% | 3904 |
|
|
2021
Q4 | $757K | Sell |
6,371
-9
| -0.1% | -$1.42K | ﹤0.01% | 3551 |
|
|
2021
Q3 | $1.27M | Buy |
6,380
+484
| +8% | +$84.6K | ﹤0.01% | 3260 |
|
|
2021
Q2 | $1.03M | Buy |
5,896
+165
| +3% | +$30K | ﹤0.01% | 3403 |
|
|
2021
Q1 | $1.14M | Sell |
5,731
-301
| -5% | -$57.7K | ﹤0.01% | 3255 |
|
|
2020
Q4 | $1.19M | Sell |
6,032
-24
| -0.4% | -$4.97K | ﹤0.01% | 3167 |
|
|
2020
Q3 | $1.07M | Buy |
6,056
+427
| +8% | +$79K | ﹤0.01% | 3088 |
|
|
2020
Q2 | $1.3M | Buy |
5,629
+1,825
| +48% | +$348K | ﹤0.01% | 2951 |
|
|
2020
Q1 | $443K | Buy |
3,804
+190
| +5% | +$32.3K | ﹤0.01% | 3437 |
|
|
2019
Q4 | $691K | Buy |
3,614
+30
| +0.8% | +$5.89K | ﹤0.01% | 3422 |
|
|
2019
Q3 | $690K | Sell |
3,584
-237
| -6% | -$46.2K | ﹤0.01% | 3370 |
|
|
2019
Q2 | $654K | Buy |
3,821
+1,361
| +55% | +$235K | ﹤0.01% | 3470 |
|
|
2019
Q1 | $495K | Buy |
2,460
+481
| +24% | +$100K | ﹤0.01% | 3561 |
|
|
2018
Q4 | $371K | Buy |
1,979
+206
| +12% | +$43.7K | ﹤0.01% | 3625 |
|
|
2018
Q3 | $424K | Buy |
1,773
+117
| +7% | +$27.3K | ﹤0.01% | 3714 |
|
|
2018
Q2 | $438K | Buy |
+1,656
| New | +$407K | ﹤0.01% | 3687 |
|
|
2018
Q1 | – | Sell |
-530
| Closed | -$72K | – | 4404 |
|
|
2017
Q4 | $72K | Hold |
530
| – | – | ﹤0.01% | 4148 |
|
|
2017
Q3 | $65K | Hold |
530
| – | – | ﹤0.01% | 4066 |
|
|
2017
Q2 | $51K | Sell |
530
-312
| -37% | -$43.1K | ﹤0.01% | 4129 |
|
|
2017
Q1 | $157K | Buy |
+842
| New | +$119K | ﹤0.01% | 3936 |
|
Other funds holding SYRE
PA
RI
PBA
VA
DCM
Bank of New York Mellon's SYRE Position: Q2 2026 in Review
Bank of New York Mellon increased its Spyre Therapeutics (SYRE) stake by 28% in Q2 2026, buying an estimated $3.93M and bringing the position to 245,193 shares worth $21.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1583.
Bank of New York Mellon first reported a position in SYRE in Q1 2017 and has held it in 35 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.
- Bank of New York Mellon held 245,193 shares of Spyre Therapeutics worth $21.8M as of Q2 2026.
- Bank of New York Mellon bought 53,798 Spyre Therapeutics shares in Q2 2026, an estimated $3.93M.
- Spyre Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1583 holding.
- Bank of New York Mellon first reported a position in Spyre Therapeutics in Q1 2017 and has held it in 35 quarters since.
- 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.